THE IMPACT OF PHOSPHOROUS CONTROL IN CHRONIC KIDNEY DISEASE (CKD) PATIENTS

Chronic Kidney Disease Mineral Bone (CKD-MBD) disorder is associated with a significant morbidity and mortality. In vitro and animal models suggest that phosphorous, calcium, parathyroid hormone and vitamin D abnormalities mediate the cardiovascular and bone diseases that characterize CKD-MBD and increase the risk of death. Currently, mineral abnormalities are corrected through phosphorous restriction, phosphate binders, calcimimetics and vitamin D administration. Nonetheless, data in humans that support the use of these compounds are still scanty, mainly based on observational studies. Thus, a considerable number of doubts and questions still challenge clinicians dealing with CKD patients and mineral metabolism imbalances. We herein critically review clinical evidence that support the use of different drugs in CKD-MBD and present recent data on the clinical relevance of phsophorous control in CKD patients.